William Blair Investment Management LLC decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 40.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,075 shares of the medical equipment provider’s stock after selling 93,522 shares during the period. William Blair Investment Management LLC owned about 0.21% of Lantheus worth $13,842,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Oregon Public Employees Retirement Fund increased its holdings in Lantheus by 0.7% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 13,559 shares of the medical equipment provider’s stock worth $1,350,000 after purchasing an additional 100 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Lantheus by 3.3% in the third quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider’s stock valued at $344,000 after buying an additional 109 shares during the period. ABS Investment Management LLC bought a new position in shares of Lantheus during the 2nd quarter worth approximately $232,974,000. Versant Capital Management Inc boosted its stake in Lantheus by 33.0% during the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 146 shares in the last quarter. Finally, State of Michigan Retirement System increased its position in Lantheus by 1.9% in the 1st quarter. State of Michigan Retirement System now owns 16,000 shares of the medical equipment provider’s stock valued at $1,214,000 after buying an additional 300 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.
Lantheus Price Performance
Shares of NASDAQ LNTH opened at $101.59 on Monday. The stock has a market capitalization of $6.64 billion, a P/E ratio of 25.02 and a beta of 0.01. The firm’s 50 day simple moving average is $100.32 and its two-hundred day simple moving average is $92.91. Lantheus Holdings, Inc. has a one year low of $51.47 and a one year high of $111.86. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 3.06.
Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.45. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The business had revenue of $389.91 million for the quarter, compared to analysts’ expectations of $355.74 million. During the same quarter in the previous year, the business posted $1.27 earnings per share. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. As a group, analysts expect that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on LNTH. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price target for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Leerink Partners set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. Brookline Capital Markets lowered shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Mizuho downgraded shares of Lantheus from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $115.00 to $109.00 in a research report on Tuesday, October 13th. Finally, CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Three analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $107.44.
Get Our Latest Report on Lantheus
Lantheus Profile
Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.
Read More
- Five stocks we like better than Lantheus
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
